18F-氟达拉滨PET淋巴瘤显像:弥漫大B细胞淋巴瘤与慢性淋巴细胞白血病患者的首次人体研究
首次人体研究评估18F-氟达拉滨PET在10例淋巴瘤患者(5例弥漫大B细胞淋巴瘤、5例慢性淋巴细胞白血病)中的肿瘤摄取、生物分布与辐射剂量学。弥漫大B细胞淋巴瘤组中受累病灶摄取值显著高于生理性非靶部位,但2例患者与18F-FDG PET结果不一致;慢性淋巴细胞白血病组摄取与临床及CT分期一致并累及骨髓。平均有效剂量为3.07±0.81 mSv,低于18F-FDG。
要点
- 18F-氟达拉滨在弥漫大B细胞淋巴瘤受累病灶的摄取值显著高于生理性非靶部位。
- 2例弥漫大B细胞淋巴瘤患者的18F-氟达拉滨与18F-FDG PET结果存在不一致。
- 慢性淋巴细胞白血病患者中18F-氟达拉滨摄取与临床及CT分期一致并累及骨髓,心肌与脑未见摄取。
核心结论
- 18F-氟达拉滨PET可能是淋巴增殖性疾病有前景的显像工具。
- 该放射性药物的辐射剂量低于18F-FDG。
- 该探针对淋巴细胞的特异性、不在反应性组织中蓄积以及检测骨髓浸润的可行性可能在淋巴瘤显像中发挥创新作用。
研究设计与样本
- 首次人体临床研究,纳入10例患者:5例弥漫大B细胞淋巴瘤和5例慢性淋巴细胞白血病。
- 静脉注射4 MBq/kg 18F-氟达拉滨后250分钟内采集6次连续部分体部PET扫描。
- 评估肿瘤摄取、生物分布和辐射剂量学,记录每个受累淋巴结区域及结外部位(特别是肝脏)的SUV。
- 所有患者接受体格检查、实验室检查和增强CT;弥漫大B细胞淋巴瘤组还考虑行18F-FDG PET。
主要发现
- 弥漫大B细胞淋巴瘤患者中,CT或18F-FDG认为异常的部位可见18F-氟达拉滨摄取增高,受累病灶SUV显著高于生理性非靶部位。
- 2例弥漫大B细胞淋巴瘤患者的18F-氟达拉滨与18F-FDG PET比较显示不一致。
- 慢性淋巴细胞白血病患者中,18F-氟达拉滨摄取与常规临床及CT分期预期受累部位(包括脾脏侵犯)一致,并在造血骨髓中显著。
- 无论疾病组,心肌或脑均未见摄取。
- 平均注射18F-氟达拉滨活度为305±76 MBq时,平均有效剂量为3.07±0.81 mSv。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This was the first-in-humans clinical study of 18F-fludarabine, which is a radiopharmaceutical for PET imaging in lymphoma, for which many issues remain controversial with the standard radiotracer 18F-FDG. Methods:18F-fludarabine PET or PET/CT was performed on 10 patients: 5 with diffuse large B-cell lymphoma (DLBCL) and 5 with chronic lymphocytic leukemia. The tumor uptake, biodistribution, and radiation dosimetry of 18F-fludarabine were evaluated. Six successive partial-body PET scans were acquired for 250 min after an intravenous 4 MBq/kg bolus of 18F-fludarabine. SUVs were recorded for each involved lymph node territory and for several extranodal sites, with particular reference to the liver. To assess the time-related uptake profile of 18F-fludarabine, PET images were analyzed by delineating volumes of interest over the uptake sites on the optimal scan for visual observation and were projected onto all coregistered scans of the same subject. Physical examination, laboratory studies, and contrast-enhanced CT were performed on all patients. For the DLBCL group, 18F-FDG PET was also considered. Results: In DLBCL patients, increased 18F-fludarabine uptake was observed in sites considered abnormal by CT or 18F-FDG, with SUVs significantly higher in involved lesions than in physiologic nontarget sites. Nonetheless, the comparison of 18F-fludarabine and 18F-FDG PET showed discrepancies in 2 patients. In chronic lymphocytic leukemia patients, the uptake of 18F-fludarabine coincided with sites expected to be involved (including splenic invasion) according to conventional clinical and CT staging and was significant in hematopoietic bone marrow. No uptake was observed, whatever the disease group, in cardiac muscle or brain. The mean effective dose from a mean injected 18F-fludarabine activity of 305 ± 76 MBq was 3.07 ± 0.81 mSv. Conclusion:18F-fludarabine PET might well be a promising tool for lymphoproliferative diseases. The radiation dose of this radiopharmaceutical is below that of 18F-FDG. The specificity of this PET probe for lymphoid cells, its absence of accumulation in reactive tissues, and its feasibility for detection of bone marrow infiltration might play an innovative role in lymphoma imaging.
引用
- Chantepie S, Hovhannisyan N, Guillouet S, et al. 18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. J Nucl Med. 2018. PMID: 29419478. doi:10.2967/jnumed.117.206920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。